Insider Selling: Spark Therapeutics, Inc. (NASDAQ:ONCE) CEO Sells 5,669 Shares of Stock
Spark Therapeutics, Inc. (NASDAQ:ONCE) CEO Jeffrey D. Marrazzo sold 5,669 shares of the stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $65.00, for a total transaction of $368,485.00. Following the sale, the chief executive officer now directly owns 235,669 shares in the company, valued at $15,318,485. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Spark Therapeutics, Inc. (ONCE) traded down 3.63% during mid-day trading on Friday, hitting $61.83. 324,158 shares of the company were exchanged. The stock’s 50 day moving average is $56.49 and its 200-day moving average is $56.95. The company’s market cap is $1.92 billion. Spark Therapeutics, Inc. has a 12-month low of $35.07 and a 12-month high of $65.99.
Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, May 9th. The biotechnology company reported ($1.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.36) by $0.34. Spark Therapeutics had a negative net margin of 745.48% and a negative return on equity of 44.06%. The firm had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.35 million. During the same quarter in the prior year, the firm posted ($0.95) EPS. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. Equities research analysts predict that Spark Therapeutics, Inc. will post ($6.90) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/07/insider-selling-spark-therapeutics-inc-nasdaqonce-ceo-sells-5669-shares-of-stock.html.
Large investors have recently modified their holdings of the stock. Janus Capital Management LLC increased its stake in shares of Spark Therapeutics by 21.4% in the first quarter. Janus Capital Management LLC now owns 458,743 shares of the biotechnology company’s stock valued at $24,468,000 after buying an additional 80,750 shares in the last quarter. Credit Suisse AG increased its stake in shares of Spark Therapeutics by 96.7% in the first quarter. Credit Suisse AG now owns 46,174 shares of the biotechnology company’s stock valued at $2,463,000 after buying an additional 22,697 shares in the last quarter. Highbridge Capital Management LLC acquired a new position in Spark Therapeutics during the first quarter worth about $227,000. Schwab Charles Investment Management Inc. boosted its position in Spark Therapeutics by 9.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 87,751 shares of the biotechnology company’s stock worth $4,681,000 after buying an additional 7,605 shares in the last quarter. Finally, KCG Holdings Inc. boosted its position in Spark Therapeutics by 9.4% in the first quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock worth $333,000 after buying an additional 538 shares in the last quarter. Institutional investors own 89.00% of the company’s stock.
A number of analysts have weighed in on ONCE shares. Stifel Nicolaus reissued a “buy” rating and set a $76.00 target price on shares of Spark Therapeutics in a report on Monday, April 10th. Cantor Fitzgerald set a $94.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday, May 9th. BidaskClub raised shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. ValuEngine raised shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. Finally, Jefferies Group LLC reissued a “hold” rating and set a $59.00 target price on shares of Spark Therapeutics in a report on Wednesday, April 26th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $68.00.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.